选择性抑制 BET 基多马因
Panagis Filippakopoulos1, Jun Qi, Sarah Picaud
1Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, UK.
Nature
|September 28, 2010
概括
研究人员开发了JQ1,一种抑制表观遗传读者蛋白质称为odomain的小分子. 这种分子通过向BRD4蛋白来治疗某些癌症具有前途,提供了一种新的治疗策略.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 化学生物学 化学生物学
- 癌症生物学 癌症生物学
背景情况:
- 表观遗传蛋白质是药物发现的关键标,但缺少质子结合模块 (体蛋白) 的抑制剂.
- 表观遗传学"写作者"和"删除者"已经取得了成功,但"读者"在很大程度上仍未成为目标.
研究的目的:
- 识别和表征小分子抑制剂的目标是代体,一种类型的表观遗传读者蛋白质.
- 在癌症中探索抑制马丁介导蛋白质-蛋白质相互作用的治疗潜力.
主要方法:
- 开发一种细胞通透的小分子,JQ1,针对乙-氨酸结合基因.
- 确定JQ1与原体和外部终端 (BET) 家族成员BRD4.4的共同晶体结构.
- 在癌症细胞系和患者衍生的异种移植模型中对JQ1进行体外和体内测试.
主要成果:
- JQ1对人类原体的一个子集,特别是BRD4.4,表现出高强度和特异性.
- 同晶体结构揭示了JQ1与BRD4的乙-氨酸腔的互补结合.
- 在BRD4依赖性癌症中,JQ1治疗导致状分化和抗增殖作用.
结论:
- JQ1代表了针对表观遗传读者蛋白相互作用的概念证明.
- 这些发现为开发基向化学探测器奠定了通用的化学支架.
- 用JQ1准BRD4显示了针对特定的,无法治愈的状癌的治疗潜力.
相关概念视频
Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.


